Paragon 28 Reports First Quarter 2022 Financial Results and Increases 2022 Net Revenue Guidance
May 9, 2022
ENGLEWOOD, Colo.–(BUSINESS WIRE)–Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended March 31, 2022 and updated its 2022 revenue guidance
- Net revenue $41.4 million for the first quarter of 2022, representing growth of 25% over the first quarter of 2021
- U.S. revenue for the first quarter of 2022 was $36.0 million, representing growth of 24% over the first quarter of 2021. Despite Covid-19 headwinds in January and early February, performance in the quarter was driven by continued strong commercial execution and contribution from new products, an expanded surgeon customer base, and increased sales rep productivity.
- International revenue for the first quarter of 2022 was $5.4 million, representing growth of 35% over the first quarter of 2021. Growth in the quarter was driven primarily by strong performances in South Africa and the United Kingdom.
- Gross margin 83.6% for the first quarter 2022 compared to 80.5% for the first quarter of 2021, reflecting lower excess and obsolete inventory expense.
- Operating expenses $43.0 million for the first quarter of 2022 compared to $26.9 million for the first quarter of 2021, reflecting an increase in Smart28 R&D investments, sales and marketing initiatives – including greater than 600 surgeons trained in the first quarter of 2022, and increased investments in sales force expansion. Plus, increased costs related to becoming a publicly traded company.
- Net loss $9.2 million for the first quarter of 2022 compared to net loss $0.5 million for the first quarter of 2021.
- Adjusted EBITDA for the first quarter of 2022 was negative $3.3 million compared to a $2.3 million gain in the first quarter of 2021.
“I am extremely proud of P28’s performance in the first quarter, which was driven by focused investments in product development and sales force expansion supported by best-in-class medical education,” said Albert DaCosta, Chairman and Chief Executive Officer. “We will continue to prioritize these investments to drive improvements in patient outcomes.”
2022 Financial Guidance
The Company expects full year 2022 net revenue to be in a range of $171.0 million to $175.0 million, representing growth of 16% to 19% compared to the full year 2021.
The foregoing forward-looking statements reflect our expectations as of today’s date. Given the number of risk factors, uncertainties and assumptions discussed, actual results may differ materially.
Webcast and Conference Call Information
Paragon 28 will host a conference call to discuss first quarter 2022 financial results on Monday, May 9, 2022, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing (844) 200-6205 for domestic callers or (646) 904-5544 for international callers, using conference ID: 990038. Live audio of the webcast will be available on the “Investors” section of the company’s website at ir.paragon28.com. The webcast will be archived and available for replay for at least 90 days after the event.
About Paragon 28, Inc.
Based in Englewood, Colo., Paragon 28 is a leading medical device company exclusively focused on the foot and ankle orthopedic market and is dedicated to improving patient lives. From the onset, Paragon 28® has provided innovative orthopedic solutions, procedural approaches and instrumentation that cover a wide range of foot and ankle ailments including fracture fixation, hallux valgus (bunions), hammertoe, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, charcot foot and orthobiologics. The company designs products with both the patient and surgeon in mind, with the goal of improving outcomes, reducing ailment recurrence and complication rates, and making the procedures simpler, consistent, and reproducible.
Forward Looking Statements
Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: Paragon 28’s potential to shape a better future for foot and ankle patients and its estimated range of net revenue for the full year 2022. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on our current expectations, estimates, and assumptions, valid only as of the date they are made, and subject to risks and uncertainties, some of which we are not currently aware. Forward‐looking statements should not be read as a guarantee of future performance or results and may not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. These forward-looking statements are based on Paragon 28’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. These risks and uncertainties are described more fully in the section titled “Risk Factors” in Paragon 28’s filings with the Securities and Exchange Commission (the “SEC”), including Paragon 28’s annual report on Form 10-K filed with the SEC on March 8, 2022. Paragon 28 does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. These forward-looking statements should not be relied upon as representing Paragon 28’s views as of any date subsequent to the date of this press release. Paragon 28’s results for the quarter ended March 31, 2022 are not necessarily indicative of our operating results for any future periods.
Use of Non-GAAP Financial Measures and Their Limitations
In addition to our results and measures of performance determined in accordance with U.S. GAAP presented in this press release, we believe that certain non-GAAP financial measures are useful in evaluating and comparing our financial and operational performance over multiple periods, identifying trends affecting our business, formulating business plans and making strategic decisions.
Adjusted EBITDA is a key performance measure that our management uses to assess our financial performance and is also used for internal planning and forecasting purposes.
We believe that Adjusted EBITDA, together with a reconciliation to net income, helps identify underlying trends in our business and helps investors make comparisons between our company and other companies that may have different capital structures, tax rates, or different forms of employee compensation. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and future prospects, and allowing for greater transparency with respect to a key financial metric used by our management in its financial and operational decision-making. Our use of Adjusted EBITDA has limitations as an analytical tool, and you should not consider these measures in isolation or as a substitute for analysis of our financial results as reported under U.S. GAAP. Some of these potential limitations include:
- other companies, including companies in our industry which have similar business arrangements, may report Adjusted EBITDA, or similarly titled measures but calculate them differently, which reduces their usefulness as comparative measures;
- although depreciation and amortization expenses are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and Adjusted EBITDA does not reflect cash capital expenditures for such replacements or for new capital expenditure requirements;
- Adjusted EBITDA also does not reflect changes in, or cash requirements for, our working capital needs or the potentially dilutive impact of stock based compensation; and
- Adjusted EBITDA does not reflect the interest expense, or the cash requirements necessary to service interest or principal payments, on our debt that we may incur.
Because of these and other limitations, you should consider our non-GAAP measures only as supplemental to other GAAP-based financial measures.